Wednesday morning brought some pain for investors as U.S. stock futures slipped lower, with the Dow futures down around 100 points. But the broader market weakness was nothing compared to what some individual stocks were facing in pre-market action.
The biggest casualty? Glaukos Corp (GKOS), which saw its shares crater in early trading after the medical technology company released preliminary fourth-quarter and full-year 2025 sales results that clearly didn't impress Wall Street. The company pegged its preliminary FY25 sales at $507 million, sending shares down 12.1% to $96.97 before the opening bell.
But Glaukos wasn't alone in the pre-market penalty box. Here's a look at other notable stocks moving lower:
Briacell Therapeutics Corp (BCTX) took the hardest hit, plunging 53.1% to $5.12 after announcing a $30 million public offering. Dilution fears clearly spooked shareholders.
Trip.com Group Ltd (TCOM) dropped 9.3% to $68.55 after confirming earlier reports that it's facing an investigation by China's SAMR (State Administration for Market Regulation) for potential anti-monopoly violations. When Chinese regulators come knocking, investors tend to head for the exits.
Pearson PLC (PSO) shares fell 7.2% to $13.36 following the education publisher's 2025 trading update, which apparently contained some disappointing guidance.
Olema Pharmaceuticals Inc (OLMA) declined 5.5% to $26.37, extending Tuesday's 3% slide and continuing a rough stretch for the biotech stock.
Fresenius Medical Care AG (FMS) fell 4.8% to $21.79 in pre-market action, though no specific catalyst was immediately apparent.
Ambitions Enterprise Management Co LLC (AHMA) dropped 4.3% to $11.81, giving back a portion of Tuesday's massive 134% surge. What goes up that fast often comes down pretty quickly too.
NovaBay Pharmaceuticals Inc (NBY) declined 3.8% to $12.55, adding to Tuesday's 3% loss in what's shaping up to be a tough week for the pharmaceutical company.
SmartRent Inc (SMRT) fell 2.3% to $1.74 in early trading, rounding out the list of pre-market decliners.